Roberta Campagna
4 Papers
Roberta Campagna is an academic researcher. The author has contributed to research in topics: Gene & Cytotoxic T cell. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
Roberta Campagna,Federica Dominelli,Maria Antonella Zingaropoli,Fabio Ciurluini,Giorgia Grilli,Alessandra Amoroso,Angelo De Domenico,Donatella Amatore,Maria Stella Lia,Enrico Cortesi,Vincenzo Picone,C. Mastroianni,Maria Rosa Ciardi,Riccardo De Santis,Florigio Lista,Guido Antonelli,Ombretta Turriziani +16 more
TL;DR: Cancer patients who received three COVID-19 vaccine doses showed lower antibody titers and weaker T-cell responses compared to healthy donors, with immunotherapy-treated patients exhibiting a stronger T-cell response, highlighting the need for booster doses.
1
Longitudinal Virological and Immunological Profile in a Case of Human Monkeypox Infection
Maria Antonella Zingaropoli,A. Parente,Blerta Kertusha,Roberta Campagna,Tiziana Tieghi,Silvia Garattini,Raffaella Marocco,Anna Carraro,Eeva Tortellini,Mariasilvia Guardiani,Federica Dominelli,Ombretta Turriziani,Maria Rosa Ciardi,Claudio Maria Mastroianni,Cosmo Del Borgo,Miriam Lichtner +15 more
TL;DR: In a male with severe proctitis, monkeypox virus DNA was detected in skin lesions, blood, the nasopharynx, and the rectum, underlying generalized viral spreading as mentioned in this paper .
Sequence analysis of respiratory syncytial virus cases reveals a novel subgroup -B strain circulating in north-central Italy after pandemic restrictions.
Alessandra Pierangeli,Fabio Midulla,Antonio Piralla,Guglielmo Ferrari,Raffaella Nenna,Antonino Maria Guglielmo Pitrolo,Amelia Licari,Gian Luigi Marseglia,Dario Abruzzese,L. Pellegrinelli,C. Galli,Sandro Binda,Danilo Cereda,Matteo Fracella,Giuseppe Oliveto,Roberta Campagna,Laura Petrarca,E. Pariani,Guido Antonelli,F. Baldanti +19 more
TL;DR: This study in north-central Italy reveals a novel RSV-B strain circulating post-pandemic, characterized by high genetic divergence, contributing to intense hospitalization peaks in 2022-2023, particularly among the elderly, and differing from pre-pandemic strains.